More Potential Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Search
IT at BI
Discover firsthand what IT does at BI #IdoIT
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
Companion Animals
Companion Animals
Animal Welfare through environmental sustainability
Producing honey and contributing to environmental sustainability during your work hours.
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
New biomass power plant Ingelheim
Boehringer Ingelheim produces its own green energy
Making a difference with data science
Our Head of Central Data Science, Brigitte Fuhr joined the team to make a difference to patients’ lives.
Company culture
Corporate culture can be an important factor in your dream job. Find out about our team spirit below and why it matters.
Gastrointestinal Cancers
Gastrointestinal Cancers
Why we may be more like our pets than we think
The bond between owners and their pets goes beyond physical resemblance as we are increasingly facing similar health problems.
Investment social engagements in Cowtribe veterinary startup
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements
Our-position
Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
A Clear Vision
Our vision is a future where earlier detection and individualized treatment will stop vision loss in its tracks, protecting and preserving eyesight, and way of life.
Ruminant parasite control in a nutshell
An exclusive drug-based approach to fight worms is dying. Dr. Ray Kaplan, from Georgia University, explains five things you need to know.
BIVF funding more than doubled to 250 M€
Boehringer Ingelheim increases funding for its corporate venture fund, the Boehringer Ingelheim Venture Fund (BIVF), from EUR 100 to 250 million
Kobe
The Kobe Pharma Research Institute takes part in the global research and development activities for human pharmaceuticals.
Partnering Culture
Partnering Culture
Our Venture Fund on the search for groundbreaking trends
The Boehringer Ingelheim Venture Fund acquires minority stakes in biotech start-ups, and even supports the majority before and during their founding.
Breakthrough introduction innovation pet parasiticides
In 2014, Boehringer introduced a new product, which became the first in a new class of isoxazoline products for flea and tick protection in dogs.
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Parasiticides
Parasiticides
Meet our team
Meet our team
PRRS vaccine discovery for swine
PRRS vaccine, an unexpected scientific discovery. Our team developed the first vaccine against Porcine Reproductive and Respiratory Syndrome in pigs.
biopharmaceuticals-in-china
Boehringer Ingelheim manufactures the first biopharmaceutical approved in China under new MAH contract manufacturing regulatory system.